Idiopathic and immune‐related pulmonary fibrosis: diagnostic and therapeutic challenges

• Main Authors: Andrew McLean‐Tooke, Irene Moore, Fiona Lake
• Format: Article
• Language: English
• Published: Wiley 2019-01-01
• Series: Clinical & Translational Immunology
• Subjects: connective tissue disease; diagnosis; interstitial lung diseases (ILDs); pulmonary fibrosis; therapeutics
• Online Access: https://doi.org/10.1002/cti2.1086

Abstract Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions sharing common clinical, radiological and histopathological features as a consequence of fibrosis of the lung interstitium. The majority of ILDs are idiopathic in nature with possible genetic predisposition, but is also well recognised as a complication of connective tissue disease or with certain environmental, occupational or drug exposures. In recent years, a concerted international effort has been made to standardise the diagnostic criteria in ILD subtypes, formalise multidisciplinary pathways and standardise treatment recommendations. In this review, we discuss some of the current challenges around ILD diagnostics, the role of serological testing, especially, in light of the new classification of Interstitial Pneumonia with Autoimmune Features (IPAF) and discuss the evidence for therapies targeted at idiopathic and immune‐related pulmonary fibrosis.